

Issues Aired on Immunizing Children With Cancer

BY DEEANNA FRANKLIN
Contributing Writer

BALTIMORE — One of the most common questions from pediatricians is when to immunize cancer patients under their care, said Dr. Patrick Brown, a pediatric oncologist at Johns Hopkins University, Baltimore.

Chemotherapy and radiation treatments leave these patients profoundly immunocompromised. Additionally, if a pa-

tient has received a bone marrow transplant (BMT), they in some ways “gain the immune system of their allogeneic donor,” he said.

“The recovery of the patient’s adaptive immunity ... takes a minimum of several months, and often a year,” he said. This is particularly true for those being treated for complications such as graft versus host disease (GVHD).

Dr. Brown advised against immunizing patients prior to BMT, because their im-

munity is completely eliminated during the week of preparation. These patients should receive no vaccinations until 6 months post BMT.

“After this, patients should be considered completely unimmunized, and therefore need to catch up,” Dr. Brown said.

Specifically, patients should get a flu shot as soon as possible after the 6 months post-BMT period, regardless of any other treatments they’re receiving, and annually from then on.

Although patients normally should not receive vaccinations during intensive sessions of chemotherapy, “The exception to that is influenza. Even though it’s variably effective during the intensive phases of therapy, the downside is so great, we do recommend immunizing patients with influenza vaccine even during intensive phases of therapy,” Dr. Brown stressed at a meeting on pediatric trends sponsored by Johns Hopkins University.

Other nonlive viral vaccines should begin no sooner than 12 months after BMT, and all should be given as boosters. The only exception to that advice is pneumococcal 7-valent conjugate vaccine (Prevnar), which is not recommended because of a lack of efficacy data in this patient group.



Family members and household contacts should receive any and all indicated vaccinations.

DR. BROWN

Dr. Brown noted that the meningococcal vaccine is safe and should be given to any patient who is at least 12 months post BMT and over 2 years old, particularly patients with chronic GVHD, who are at markedly increased risk of infections with encapsulated organisms such as meningococcus.

He advises waiting 2 years before immunizing patients with live vaccines such as MMR—the only live-virus vaccine shown to be safe for this patient group. The varicella vaccine is “relatively” contraindicated for this patient group because its safety profile is still unknown.

“All family members and household contacts can and should receive any and all indicated vaccinations, including live-virus vaccines,” Dr. Brown said.

Flu vaccinations are particularly encouraged, he added.

According to Dr. Brown, when it comes to nontransplant cancer therapy and the status of protective antibody titers, approximately 50% of patients will lose their hepatitis B immunity, 25% will lose their MMR immunity, 15% will lose tetanus immunity, and about 10% will lose polio immunity.

Younger patients are more likely to lose their immunity. “The rate of recovery of protective antibody titers after giving boosters post chemotherapy is very, very high,” he said.

He recommended the Web site www.curesearch.org, which is the National Childhood Cancer Foundation Children’s Oncology Group site. It also includes useful information for families.

Providers may also go directly to www.survivorshipguidelines.org, which offers long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers, and includes “health links,” which are educational documents to download and give to patients and their families. ■

ADVERTORIAL

MISMATCH MISCHIEF: THE IMPACT OF DRIFTED INFLUENZA STRAINS

Influenza vaccines have been available for over half a century. Yet year after year, influenza continues to place a huge burden on society—both in children and in adults.¹ Influenza affects between 5% to 20% of the US population every year, resulting in up to 25 million doctor visits and over 200,000 hospitalizations.^{2,4}

One factor contributing to influenza’s heavy toll is vaccine mismatch.⁵ Each year the World Health Organization (WHO) selects influenza strains for the vaccine well in advance of the flu season. Vaccine mismatch occurs when the circulating strains do not match those chosen for the vaccine.

VACCINE MISMATCH—FREQUENCY AND SEVERITY

Mismatched strains occur frequently and may cause severe consequences⁵:

Season	Vaccine Strain	Drifted Strain	Drifted in Mismatched Type
2005-2006	B/Shanghai	B/Victoria	81%
2004-2005	A(H3N2)/Wyoming	A(H3N2)/California	78%
2003-2004	A(H3N2)/Panama	A(H3N2)/Fujian	89%
2000-2001	B/Beijing	B/Sichuan	89%
1997-1998	A(H3N2)/Wuhan	A(H3N2)/Sydney	81%

- Vaccine mismatch has occurred in 5 of the last 10 influenza seasons⁵⁻⁹
- During the 2003-2004 influenza season, when 89% of circulating A-strains were mismatched, 153 children—nearly half of whom were previously healthy—died from influenza-related causes¹⁰
- In one study, children under age 5 had **nearly twice** as many influenza-associated outpatient clinic visits and **more than 4 times** as many influenza-associated emergency room visits in the mismatched season of 2003-2004 than in the matched season of 2002-2003¹¹

MISMATCH MAY DIMINISH VACCINE EFFICACY¹²

In one study during the 1998-1999 influenza season, when vaccine strains and circulating strains were well-matched, the efficacy of the inactivated influenza vaccine against laboratory-confirmed influenza in healthy adults was 86%. During the 1997-1998 season, when the vaccine and circulating strains were mismatched, the efficacy of inactivated vaccine was just 50%.¹²

MedImmune is a biotechnology company committed to helping reduce influenza morbidity and mortality and to developing innovative solutions to improve vaccination strategies.

References: 1. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR*. 2006;55(Full Release):1-42. 2. Centers for Disease Control and Prevention. Key facts about influenza and the influenza vaccine. Available at: <http://www.cdc.gov/flu/keyfacts.htm>. Accessed September 21, 2006. 3. Couch RB. Influenza: prospects for control. *Ann Intern Med*. 2000;133:992-998. 4. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. *JAMA*. 2004;292:1333-1340. 5. Centers for Disease Control and Prevention. Update: influenza activity—United States, 1997-98 season. *MMWR*. 1998;47:196-200. 6. Centers for Disease Control and Prevention. 2005-06 U.S. influenza season summary. Available at: <http://www.cdc.gov/flu/weekly/weeklyarchives2005-2006/05-06summary.htm>. Accessed November 7, 2006. 7. Centers for Disease Control and Prevention. Update: influenza activity—United States and worldwide, 2004-05 season. *MMWR*. 2005;54(25):631-634. 8. Centers for Disease Control and Prevention. Update: influenza activity—United States and worldwide, 2003-04 season. *MMWR*. 2004;53:284-287. 9. Centers for Disease Control and Prevention. Update: influenza activity—United States and worldwide, 2000-01 season, and composition of the 2001-02 influenza vaccine. *MMWR*. 2001;50(22):466-470. 10. Bhat N, Wright JG, Broder KR, et al. Influenza-associated deaths among children in the United States, 2003-2004. *N Engl J Med*. 2005;353:2559-2567. 11. Poehling KA, Edwards KM, Weinberg GA, et al. The underrecognized burden of influenza in young children. *N Engl J Med*. 2006;355:31-40. 12. Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. *JAMA*. 2000;284:1655-1663.

MedImmune
Gaithersburg, MD 20878

©2006 MedImmune Vaccines, Inc. FLU06-136